Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this metabolic disorder, but Vogenx aims to stand apart by offering patients a different mechanism of action and oral dosing.
The bottleneck in AI-enabled real-world data analysis is not computation, model architecture, or training data volume. It is the semantic layer over which the AI is trying to reason – the place where precise clinical meaning lives.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma.
Sangamo Therapeutics filed for Chapter 11 bankruptcy in June after its search for strategic alternatives failed to find a path forward for the company. PTC Therapeutics’ auction win brings a Sangamo gene therapy candidate for Fabry disease, a rare inherited disorder with few treatment options.
Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead programs entering the clinic in atopic dermatitis.
Tanvi Patel, vice president and general manager of Amazon Pharmacy, and her co-panelists at the recent Bullseye event, explained why PBMs, payers and doctors are all hampering consumer choice when it comes to patients getting affordable drugs.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Jazz Pharmaceuticals, maker of the blockbuster epilepsy drug Epidiolex, is acquiring Actio Biosciences and its lead drug in pivotal testing for a rare type of epilepsy with no FDA-approved treatments. It’s Jazz’s second epilepsy deal in the past year.
Drug development isn't limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence.
Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies.
A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals' use of contract pharmacies and adding new transparency and compliance rules. The legislation would also kill HHS' contested rebate pilot within a year and replace it with a national data clearinghouse to catch duplicate discounts.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev, positions it as a more convenient alternative to an Iovance Biotherapeutics cell therapy that had been the only treatment in this setting.
QuantHealth raised $45 million in Series B funding to expand its AI platform, which simulates clinical trials before they run and predicts patient outcomes for pharma companies. The startup is aiming to cut the industry's 90% trial failure rate and speed up the timelines for effective drugs to reach the market.
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company's cancer drug pipeline.
M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression, and Parkinson’s disease.
Apnimed will apply the IPO proceeds toward the regulatory process and launch plans of Oxnimbi, a once-nightly pill developed for obstructive sleep apnea. This drug is under FDA review with a February 2027 target date for a regulatory decision.